Elona Cekani1, José Luis López-Guerra2, Rodrigo Barrientos1, Patricia Tavera3, Juan Manuel Praena-Fernandez4, Eleonor Rivin Del Campo5, Ignacio Azinovic3, Raul Matute6. 1. Máster Internacional en Aplicaciones Tecnológicas Avanzadas en Oncología Radioterápica de la Universidad de Murcia, GenesisCare Fundación, Madrid, Spain. 2. Department of Radiation Oncology, University Hospital Virgen del Rocio, Sevilla, Spain. 3. Department of Radiation Oncology, GenesisCare, Madrid, Spain. 4. Methodology Unit, University Hospital Virgen del Rocio, Spain. 5. Department of Radiation Oncology, Tenon University Hospital, Paris, France. 6. Department of Radiation Oncology, University Hospital La Paz, Madrid, Spain.
Abstract
AIM: The purpose of this study is to evaluate the long term tolerability of hypofractionated helical tomotherapy (HT) in localized prostate cancer patients. BACKGROUND: Previous hypofractionated schedules with conventional RT were associated with excessive toxicity, likely due to inadequate sophistication of treatment delivery. There are few data about late toxicity after HT. MATERIALS AND METHODS: We evaluated 38 patients with primary adenocarcinoma of the prostate. There were 9 (24%), 15 (39%), and 14 (37%) patients with high, intermediate, and low risk, respectively. Patients were treated with hypofractionated HT from May 2008 to February 2011. Hypofractionation regimens included: 68.04 Gy at 2.52 Gy/fraction (N = 25; 66%), 70 Gy at 2.5 Gy/fraction (N = 4; 11%) and 70.2 Gy at 2.6 Gy/fraction (N = 9; 23%). Late genitourinary (GU) and gastrointestinal (GI) toxicity was scored using the Radiation Therapy Oncology Group scoring system. RESULTS: Median age at diagnosis was 70 years (range 49-80) and median follow-up, 5.8 years. Late grade 1, 2 and 3 GI toxicity were 13%, 24%, and 2.6%, respectively. Late grade 1, 2, 3 GU toxicity were 29%, 21%, and 8%, respectively. Sexual toxicity was evaluated in 19 patients to be grade 1, 2 in 11% and grade 3 in 16%. Multivariate analysis showed that patients with higher values of rectum V50 associated with late GI toxicity (P = 0.025). Patients with PSA ≤8 (P = 0.048) or comorbidities (P = 0.013) at diagnosis were associated with higher late GU toxicity. Additionally, PSA ≤8 also associated with moderate (grade ≥2) late GU toxicity in the multivariate analysis (P = 0.028). CONCLUSIONS: Hypofractionated HT can be delivered safely with limited rates of moderate and severe late toxicity. The proportion of the rectum that receives a moderate and high dose, having comorbidities, and PSA at diagnosis seem to associate with long term toxicity.
AIM: The purpose of this study is to evaluate the long term tolerability of hypofractionated helical tomotherapy (HT) in localized prostate cancer patients. BACKGROUND: Previous hypofractionated schedules with conventional RT were associated with excessive toxicity, likely due to inadequate sophistication of treatment delivery. There are few data about late toxicity after HT. MATERIALS AND METHODS: We evaluated 38 patients with primary adenocarcinoma of the prostate. There were 9 (24%), 15 (39%), and 14 (37%) patients with high, intermediate, and low risk, respectively. Patients were treated with hypofractionated HT from May 2008 to February 2011. Hypofractionation regimens included: 68.04 Gy at 2.52 Gy/fraction (N = 25; 66%), 70 Gy at 2.5 Gy/fraction (N = 4; 11%) and 70.2 Gy at 2.6 Gy/fraction (N = 9; 23%). Late genitourinary (GU) and gastrointestinal (GI) toxicity was scored using the Radiation Therapy Oncology Group scoring system. RESULTS: Median age at diagnosis was 70 years (range 49-80) and median follow-up, 5.8 years. Late grade 1, 2 and 3 GI toxicity were 13%, 24%, and 2.6%, respectively. Late grade 1, 2, 3 GU toxicity were 29%, 21%, and 8%, respectively. Sexual toxicity was evaluated in 19 patients to be grade 1, 2 in 11% and grade 3 in 16%. Multivariate analysis showed that patients with higher values of rectum V50 associated with late GI toxicity (P = 0.025). Patients with PSA ≤8 (P = 0.048) or comorbidities (P = 0.013) at diagnosis were associated with higher late GU toxicity. Additionally, PSA ≤8 also associated with moderate (grade ≥2) late GU toxicity in the multivariate analysis (P = 0.028). CONCLUSIONS: Hypofractionated HT can be delivered safely with limited rates of moderate and severe late toxicity. The proportion of the rectum that receives a moderate and high dose, having comorbidities, and PSA at diagnosis seem to associate with long term toxicity.
Entities:
Keywords:
Helical tomotherapy; Hypofractionation; Late toxicity; Prostate cancer; Radiation therapy
Authors: Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Himu Lukka; Charles Hayter; Jim A Julian; Padraig Warde; W James Morris; Mary Gospodarowicz; Mark Levine; Jinka Sathya; Richard Choo; Hugh Prichard; Michael Brundage; Winkle Kwan Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Eric E Yeoh; Richard H Holloway; Robert J Fraser; Rochelle J Botten; Addolorata C Di Matteo; Julie Butters; Sujeeva Weerasinghe; Prasad Abeysinghe Journal: Int J Radiat Oncol Biol Phys Date: 2006-09-11 Impact factor: 7.038
Authors: Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Carlos Vargas; Alvaro Martinez; Larry L Kestin; Di Yan; Inga Grills; Donald S Brabbins; David M Lockman; Jian Liang; Gary S Gustafson; Peter Y Chen; Frank A Vicini; John W Wong Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Peter C O'Brien; C Ian Franklin; Michael G Poulsen; David J Joseph; Nigel S Spry; James W Denham Journal: Int J Radiat Oncol Biol Phys Date: 2002-10-01 Impact factor: 7.038
Authors: Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-04 Impact factor: 7.038
Authors: Sara Junius; Karin Haustermans; Barbara Bussels; Raymond Oyen; Bianca Vanstraelen; Tom Depuydt; Jan Verstraete; Steven Joniau; Hendrik Van Poppel Journal: Radiat Oncol Date: 2007-08-08 Impact factor: 3.481
Authors: David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar Journal: Lancet Oncol Date: 2007-06 Impact factor: 41.316